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Abstract
Patients who present with unilateral vestibular schwannomas either at a young age or with additional features of type 2 neurofibromatosis (NF2) are at risk of developing bilateral disease and transmitting a risk of neurogenic tumours to their offspring. We have identified 15 patients from a series of 537 with unilateral vestibular schwannomas who also had one or more of the following: other tumours (10115), features of NF2 (3/15), or a family history of neurogenic tumours (5115) . No germline NF2 mutations were detected and in 7/9 cases where tumour material was available for analysis a germline mutation in the NF2 gene has been excluded. Although a possibility of gonosomal mosaicism still exists, exclusion tests for the offspring are now possible. We suggest a general strategy, based on analysis of tumour DNA, for distinguishing sporadic and familial cases of tumours caused by two hit mechanisms. Application of this strategy suggests that most instances of unilateral vestibular schwannoma which do not fulfil criteria for NF2 represent chance occurrences. (JMed Genet 1998; 35:973-977) Keywords: neurofibromatosis type 2; vestibular schwannoma; somatic mosaicism; mutation The majority of patients presenting with vestibular schwannomas (VS) have noninherited tumours that carry no further implications for the patient or family. Some, however, have type 2 neurofibromatosis (NF2, MIM 101000), an autosomal dominant inherited condition characterised by the development of bilateral VS, schwannomas of other cranial, spinal, and cutaneous nerves, and cranial and spinal meningiomas.'-' Diagnosis of NF2 has profound implications both for the patient and his relatives. Usually the distinction is readily made between sporadic unilateral VS and familial NF2 with bilateral VS and other signs. However, some 10-20% of NF2 cases present initially with a unilateral VS.2-4 When a patient with unilateral VS has a relative with unilateral VS (but not classical NF2), or has one or a few other features of NF2 without a family history, the differential diagnosis can be difficult. In these cases comparative analysis of DNA from the tumour and from the patient's blood may allow a correct diagnosis.
Vestibular schwannomas arise by a classical two hit mechanism5 from cells that have functionally or physically lost both copies of the NF2 gene. In sporadic VS both losses occur by somatic mutations in a genetically normal subject, while patients with NF2 inherit one mutation, which is present in every cell of their body. The picture is complicated by the frequent occurrence of genetic mosaicism, in which one mutation occurs early in embryonic development in a previously normal person6; such people have no family history ofNF2 but are at risk of passing the mutation on to their children if it is present in the germline.
The NF2 gene was mapped to 22q12 in 19887 and isolated in 19938 and several reports have documented germline mutations in large series of affected cases.10-14 Unfortunately, standard mutation detection techniques such as single strand conformational polymorphisms (SSCP) or denaturing gradient gel electrophoresis (DGGE) do not detect mutations in every classically affected patient, so that failure to detect a mutation in DNA from the patient's blood cannot be used as a means of excluding NF2. We have previously reported a series of patients with unilateral VS and other features suggestive of NF2.
" Until the risk of other tumours can be minimised by exclusion of a germline NF2 mutation, these people and their children need continuing screening.
We have now analysed tumour material from nine of these subjects to establish whether mutations present in the tumour are the result of germline or mosaic disease, or are purely somatic events representing chance occurrences in these patients and families. This analysis suggests an approach that may be generally applicable to distinguishing inherited from sporadic tumours in two hit diseases.
Patients and methods
We studied patients who presented with unilateral vestibular schwannoma but who on further enquiry showed other diagnostic criteria of NF2 or a family history of vestibular schwannoma or meningioma. Between January 1978 and August 1994, a total of 407 patients with unilateral VS were seen at our joint neurosurgery/otology unit. Since 1990, all patients have been assessed by magnetic resonance imaging with gadolinium enhancement, so that any other cranial tumour would almost certainly have been identified. In an earlier study, 93 of the 407 patients were leading to a wrong diagnosis of NF2. The annual incidence rate for VS is now thought to be around 1 in 80 000 (Thomsen, personal communication), a little higher than the rate of 1 per 100 000 previously proposed.2" Thus, the lifetime risk of a VS is likely to be around 1 per 1000 (1 per 2000 for each eighth nerve) and one person per 2 million of the population would be expected to develop bilateral disease as two independent sporadic events. As the birth incidence of NF2 is 1 in 35 000,26 it seems possible that 2% of patients classified as having NF2 actually may have sporadic bilateral VS. In practice, a diagnosis of NF2 is less likely in older patients, patients with a long interval between two VSs, and patients with a history of exposure to environmental risk factors. However, coincidence is extremely unlikely if subjects develop bilateral VS at young ages or have additional features of NF2. Our present series was made of cases that did not fulfil NIH criteria. There are two groups of patients who do not fulfil these criteria but where the possibility of NF2 seems real: patients with several NF2 features (multiple neurogenic tumours or one neurogenic tumour plus other NF2 associated symptoms), and patients with a family history of isolated neurogenic tumours. We suggested23 additional criteria for NF2 which are listed in table 3. We recently showed that in six of 17 cases that fulfilled these modified NF2 criteria (presenting at other clinics and not included in the present series) a germline mutation could be found.6 This detection rate is comparable to that seen for classical NF2," 12 suggesting that the modified criteria are valid. However, in the present series, although four patients (13, 5, 8, and 9) fulfilled the modified criteria, no germline mutations have been found and in two of these (patients 5 and 9) germline mutations have been excluded by showing both hits in the tumour, neither of which was present in blood. These results do not invalidate the modified criteria. At least one of these patients (patient 9) is almost certainly mosaic. Additionally, we have recently shown that many cases of classical NF2 are also mosaic. 6 Subjects fulfilling these modified criteria will mostly be at risk of further tumours and many will be at risk of transmitting a mutated NF2 gene to their children.
Sporadic unilateral VS will sometimes appear to be familial. The average person in the UK is likely to have five first degree and 10 second degree relatives, so that our series of 537 patients with unilateral VS would have around 2685 first degree and 5000 second degree relatives. Given the lifetime risk of 1 in 1000 of VS, two to three cases of sporadic vestibular schwannoma would be expected to occur in the first degree relatives of our series. In the event, only one pair of affected first degree relatives has been identified (two sisters, patients 2 and 3). Our molecular studies have shown that their tumours are unrelated and thus a chance association. Patient 2 shows two hits in the tumour, neither of which is present in her blood, while no germline mutation could be detected in her sister (patient 3); tumour from patient 3 was not available. It is likely that the majority of cases of isolated vestibular schwannoma occurring in close relatives are entirely coincidental.
In this study we have shown that the majority of patients presenting with histories suggestive of NF2, but in whom classical criteria are not met, do not have germline mutations in the NF2 gene. We were also able to exclude germline NF2 mutations in a patient (4) with the association of five cafe au lait patches with an early onset VS, and a patient (7) with cataract with a unilateral tumour. The same is likely to be true for many instances of a single NF2 related tumour occurring in association with a unilateral vestibular schwannoma. However, some patients may be somatic mosaics, particularly those with another definitive feature of NF2 in addition to their VS. In true mosaic cases, both tumours would contain a mutation in common. The spectrum of mutations found in the tumours was similar to other series of unilateral vestibular schwannoma.27 In those cases that are mosaic it may be possible to make tentative assumptions about disease severity in offspring based on the type of mutation.3 14 It might be expected that the two splice site mutations, if mosaic in the gonads, would be associated with milder disease in any affected offspring.
Comparing constitutional and tumour DNA, including comparisons in multiple tumours or multiple affected relatives, offers a useful approach to excluding germline mutations. In many tumour prone disorders such as NF1, familial adenomatous polyposis, retinoblastoma, and von Hippel-Lindau disease, patients may be subjected to continuing screening and worry even though no mutation was detected on analysis of their blood DNA. This is because it is not possible to identify mutations in all classically affected subjects, and therefore failure to detect a mutation does not exclude the diagnosis. This is particularly the case for children or sibs of patients with unilateral retinoblastoma. Although the risk of a sib being affected is only 1-2%,28 it is still routine practice to screen these children in the same way as those at 50% risk. This can entail repeated general anaesthetics with the associated trauma to the child, worry for the parents, and costs for the Health Service. As table 4 shows, identification of both mutations (or one mutation plus loss of heterozygosity) in the tumour and exclusion of these in the germline of the 
